The US Food and Drug Administration (FDA) has authorised the marketing of Inflammatix’s blood test, the TriVerity Test System, designed to aid in diagnosing individuals with suspected acute infection or sepsis.
The molecular test quantifies the expression levels of 29 genes linked to the body’s immune reaction to infection.
Go deeper with GlobalData
By employing ‘validated’ algorithms, which are driven by machine learning and AI, the test produces three distinct scores that assess the probability of bacterial infection, viral infection, and severe illness risk.
The system claims to alleviate the challenges that hospitals face, particularly in emergency departments (EDs) struggling with overcrowding and extended patient stays.
It also claims to provide a measure of infection likelihood and risk stratification and can help potentially reduce unnecessary hospital admissions and improve patient care.
The FDA’s authorisation of the system is supported by the findings from the SEPSIS-SHIELD study, which demonstrated the test’s ‘high’ diagnostic and ‘prognostic’ accuracy in a diverse patient population.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn November 2023, the system received the FDA’s breakthrough device designation.
Inflammatix CEO and co-founder Tim Sweeney said: “The fundamental problem with existing tests is an outdated focus on labelling patients as ‘septic or not.’ But sepsis is a syndrome, not a disease, and its definition keeps changing.”
Developed from research conducted at Stanford University by co-founders Tim Sweeney and Purvesh Khatri, the system incorporates ‘exclusive’ intellectual property licensed by the university.
Headquartered in California, US, Inflammatix focuses on the use of machine learning in molecular diagnostics to interpret the immune response rapidly.
Last November, the company initiated a clinical trial to evaluate the test for managing individuals with suspected acute infection or sepsis.
